 Kathryn Beauchamp
Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endotamponade | 2 | 2015 | 4 | 1.020 |
Why?
| | Brain Injuries | 8 | 2015 | 452 | 0.990 |
Why?
| | Intracranial Hemorrhages | 2 | 2015 | 76 | 0.960 |
Why?
| | Intraoperative Complications | 2 | 2015 | 121 | 0.930 |
Why?
| | Decompressive Craniectomy | 3 | 2014 | 8 | 0.910 |
Why?
| | Craniotomy | 2 | 2015 | 67 | 0.910 |
Why?
| | Intracranial Hypertension | 3 | 2014 | 37 | 0.870 |
Why?
| | Cranial Fossa, Posterior | 1 | 2015 | 16 | 0.520 |
Why?
| | Craniosynostoses | 1 | 2015 | 28 | 0.500 |
Why?
| | Arnold-Chiari Malformation | 1 | 2015 | 30 | 0.500 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 152 | 0.460 |
Why?
| | Cerebellum | 1 | 2015 | 200 | 0.440 |
Why?
| | Hypertension, Malignant | 1 | 2013 | 2 | 0.440 |
Why?
| | Brain Damage, Chronic | 1 | 2013 | 19 | 0.440 |
Why?
| | Cerebral Infarction | 1 | 2013 | 39 | 0.430 |
Why?
| | Neurologic Examination | 1 | 2013 | 114 | 0.420 |
Why?
| | Cervical Vertebrae | 2 | 2010 | 100 | 0.400 |
Why?
| | Hospital Mortality | 1 | 2015 | 776 | 0.380 |
Why?
| | Hypothermia, Induced | 1 | 2010 | 66 | 0.340 |
Why?
| | Football | 1 | 2010 | 76 | 0.330 |
Why?
| | Skull | 1 | 2010 | 119 | 0.330 |
Why?
| | Craniocerebral Trauma | 1 | 2010 | 128 | 0.320 |
Why?
| | Spinal Cord Injuries | 2 | 2013 | 172 | 0.310 |
Why?
| | Treatment Outcome | 8 | 2015 | 9089 | 0.240 |
Why?
| | Vertebral Artery | 2 | 2014 | 26 | 0.230 |
Why?
| | Glasgow Coma Scale | 3 | 2015 | 143 | 0.230 |
Why?
| | Carotid Artery Injuries | 2 | 2014 | 43 | 0.230 |
Why?
| | Postoperative Complications | 2 | 2013 | 2127 | 0.220 |
Why?
| | Head Injuries, Penetrating | 2 | 2015 | 7 | 0.220 |
Why?
| | Head Injuries, Closed | 2 | 2015 | 47 | 0.200 |
Why?
| | Complement Membrane Attack Complex | 2 | 2020 | 33 | 0.190 |
Why?
| | Wounds, Nonpenetrating | 2 | 2014 | 223 | 0.190 |
Why?
| | Spinal Fractures | 2 | 2013 | 75 | 0.160 |
Why?
| | Survival Rate | 2 | 2015 | 1642 | 0.160 |
Why?
| | Frontal Bone | 1 | 2017 | 13 | 0.150 |
Why?
| | Facial Injuries | 1 | 2017 | 19 | 0.140 |
Why?
| | Sampling Studies | 1 | 2015 | 93 | 0.130 |
Why?
| | Brain Injuries, Traumatic | 1 | 2020 | 300 | 0.130 |
Why?
| | Injury Severity Score | 3 | 2014 | 456 | 0.130 |
Why?
| | Infant | 4 | 2015 | 7932 | 0.120 |
Why?
| | Humans | 18 | 2020 | 114709 | 0.120 |
Why?
| | Risk Assessment | 2 | 2015 | 2973 | 0.120 |
Why?
| | Carotid Artery, Internal | 1 | 2014 | 36 | 0.110 |
Why?
| | Intracranial Pressure | 1 | 2014 | 47 | 0.110 |
Why?
| | Fracture Fixation | 2 | 2013 | 76 | 0.110 |
Why?
| | Biomechanical Phenomena | 1 | 2015 | 667 | 0.100 |
Why?
| | Thoracic Vertebrae | 1 | 2013 | 68 | 0.100 |
Why?
| | Male | 10 | 2015 | 55554 | 0.100 |
Why?
| | Fractures, Bone | 1 | 2017 | 367 | 0.100 |
Why?
| | Phenytoin | 1 | 2012 | 13 | 0.100 |
Why?
| | Piracetam | 1 | 2012 | 14 | 0.100 |
Why?
| | Adult | 10 | 2017 | 30542 | 0.100 |
Why?
| | Young Adult | 4 | 2015 | 10461 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2268 | 0.090 |
Why?
| | Lumbar Vertebrae | 1 | 2013 | 209 | 0.090 |
Why?
| | Stents | 1 | 2014 | 475 | 0.090 |
Why?
| | Endovascular Procedures | 1 | 2014 | 268 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2012 | 178 | 0.090 |
Why?
| | Femoral Fractures | 1 | 2010 | 67 | 0.080 |
Why?
| | CD59 Antigens | 1 | 2009 | 21 | 0.080 |
Why?
| | Brain Edema | 1 | 2009 | 60 | 0.080 |
Why?
| | Middle Aged | 6 | 2015 | 26747 | 0.080 |
Why?
| | Seizures | 1 | 2012 | 339 | 0.080 |
Why?
| | Female | 9 | 2017 | 59483 | 0.080 |
Why?
| | Blood-Brain Barrier | 1 | 2009 | 106 | 0.080 |
Why?
| | Pipecolic Acids | 1 | 2008 | 23 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2537 | 0.080 |
Why?
| | Cyclosporine | 1 | 2008 | 161 | 0.070 |
Why?
| | Acute Disease | 1 | 2010 | 912 | 0.070 |
Why?
| | Wounds, Gunshot | 1 | 2010 | 188 | 0.070 |
Why?
| | Encephalitis | 1 | 2009 | 127 | 0.070 |
Why?
| | Laminectomy | 1 | 2007 | 24 | 0.070 |
Why?
| | Tissue and Organ Procurement | 1 | 2010 | 228 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2015 | 984 | 0.070 |
Why?
| | Child, Preschool | 3 | 2015 | 9077 | 0.070 |
Why?
| | Progesterone | 1 | 2008 | 232 | 0.070 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2008 | 181 | 0.070 |
Why?
| | Recovery of Function | 1 | 2010 | 572 | 0.070 |
Why?
| | Burns | 1 | 2009 | 237 | 0.060 |
Why?
| | Databases, Factual | 1 | 2010 | 1126 | 0.060 |
Why?
| | Joint Instability | 1 | 2007 | 162 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 498 | 0.060 |
Why?
| | Spinal Fusion | 1 | 2007 | 200 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2015 | 5034 | 0.060 |
Why?
| | Adolescent | 4 | 2015 | 17806 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 934 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2009 | 3542 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2014 | 12511 | 0.050 |
Why?
| | Child | 3 | 2015 | 18348 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1630 | 0.050 |
Why?
| | Quality of Life | 1 | 2010 | 2356 | 0.040 |
Why?
| | Complement Activation | 1 | 2020 | 340 | 0.040 |
Why?
| | Length of Stay | 2 | 2013 | 949 | 0.040 |
Why?
| | Brain | 1 | 2009 | 2369 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2020 | 285 | 0.040 |
Why?
| | Prospective Studies | 2 | 2020 | 6215 | 0.030 |
Why?
| | Biomarkers | 2 | 2020 | 3414 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2014 | 4420 | 0.030 |
Why?
| | Intracranial Thrombosis | 1 | 2014 | 17 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 2014 | 109 | 0.030 |
Why?
| | Accidents, Traffic | 1 | 2014 | 166 | 0.030 |
Why?
| | Animals | 3 | 2009 | 31761 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2014 | 6346 | 0.030 |
Why?
| | Propensity Score | 1 | 2014 | 224 | 0.030 |
Why?
| | Fibrinolytic Agents | 1 | 2014 | 233 | 0.020 |
Why?
| | Cost Control | 1 | 2012 | 38 | 0.020 |
Why?
| | Decision Trees | 1 | 2012 | 80 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2013 | 232 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2012 | 137 | 0.020 |
Why?
| | Time Factors | 2 | 2013 | 6122 | 0.020 |
Why?
| | Drug Costs | 1 | 2012 | 91 | 0.020 |
Why?
| | Third-Party Consent | 1 | 2010 | 8 | 0.020 |
Why?
| | Brain Death | 1 | 2010 | 31 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2009 | 4710 | 0.020 |
Why?
| | Critical Pathways | 1 | 2010 | 74 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2009 | 30 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 545 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2009 | 58 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2009 | 45 | 0.020 |
Why?
| | fas Receptor | 1 | 2009 | 92 | 0.020 |
Why?
| | Trauma Centers | 1 | 2010 | 325 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2009 | 75 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 213 | 0.020 |
Why?
| | Zygapophyseal Joint | 1 | 2007 | 7 | 0.020 |
Why?
| | Arthrography | 1 | 2007 | 22 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2009 | 460 | 0.020 |
Why?
| | Aged | 2 | 2014 | 19078 | 0.020 |
Why?
| | Mice | 2 | 2009 | 14916 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2009 | 2582 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2557 | 0.010 |
Why?
| | Neurons | 1 | 2009 | 1280 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2369 | 0.010 |
Why?
|
|
Beauchamp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|